Furthermore, mGluR1-positive melanoma cells were more sensitive to riluzole than were normal melanocytes or mGluR1-negative melanoma cells, supporting the notion of riluzole being a selective agent in targeted therapy [158,170]. Here, GRM1 is linked to melanoma.